Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 avr. 2026 16h46 HE | Source: The Rosen Law Firm PA

INO FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INO

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October...
02 avr. 2026 16h11 HE | Source: Hagens Berman Sobol Shapiro LLP

QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data

Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
02 avr. 2026 16h05 HE | Source: Candel Therapeutics

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
02 avr. 2026 16h05 HE | Source: Minerva Neurosciences, Inc

Minerva Announces Leadership Transition

BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
02 avr. 2026 16h05 HE | Source: Athyrium Capital Management, LP

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

Athyrium Funds purchased a portion of the royalties payable to Esperion on Japan net sales of Otsuka’s bempedoic acid products, together with related milestone payments, subject to a cap, for total...
02 avr. 2026 16h00 HE | Source: Esperion Therapeutics, Inc.

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion’s Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued...
02 avr. 2026 15h54 HE | Source: PawPrint Labs

PawPrint Protocol Claims Evaluated: The Most Effective Liquid Dog NAD+ NMN Supplement for Pets

PawPrint Protocol NAD+ NMN nanoliposomal liquid dog supplement: ingredient research, dosing, pricing, and 90-day guarantee details for 2026.
02 avr. 2026 15h26 HE | Source: MediWound Ltd.

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic...
02 avr. 2026 14h46 HE | Source: The Rosen Law Firm PA

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – CORT

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between...
02 avr. 2026 14h45 HE | Source: Derila

Derila ERGO Memory Foam Pillow Under Investigation: Concealed Consumer Report Reveals Dangerous Scam Risks

Addressing "Derila Ergo scam" searches, unspecified certifications, China fulfillment, fictional review names, and pre-purchase verification steps

Page précédente

Page suivante